Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JIN-A02
- Development stage
- Phase 2
- Lead developer
- J INTS BIO
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JIN-A02 is a novel, orally administered, fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by J INTS BIO. It is designed to selectively and reversibly inhibit EGFR mutations, specifically targeting the C797S and T790M mutations that frequently drive resistance to third-generation EGFR-TKIs like osimertinib. JIN-A02 exhibits high selectivity for mutant EGFR over wild-type EGFR, potentially reducing off-target toxicities. Preclinical and early clinical data indicate that the compound can penetrate the blood-brain barrier, showing activity against intracranial metastases. It is currently being evaluated in Phase 1/2 clinical trials for patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on prior EGFR-TKI therapies.
02
Targets
Beyond the preview
Go deeper on JIN-A02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JIN-A02.